Submitted by ROrritt on 30 November 2017
Antifungal prophylaxis is a common precaution against invasive fungal infection for patients with haematological malignancies, or those undergoing hematopoietic stem cell transplantation (HSCT). Itraconazole is a common choice due to its broad spectrum of activity.
SUBA-itraconazole (Super Bioavailability itraconazole) is a new formulation developed to improve upon the bioavailability and gastrointestinal tolerability of itraconazole.
57 patients participated in a cohort study to assess the time to achieve therapeutic levels, efficacy and tolerability of SUBA-itraconazole, compared to itraconazole. Therapeutic levels were achieved faster in the SUBA-itraconazole group and there was significantly less interpatient variability in serum concentrations, but more patients (52%) required a reduction due to supratherepeutic levels. Gastrointestinal tolerability of SUBA-itraconazole was imporved over that of itraconazole.
The authors of this study suggest that SUBA-itraconazole could be a superior formulation to itraconazole when used prophylactically in intermediate or high-invasive fungal infection-risk patients, but highlight the importance of therapeutic drug monitoring in both cases.
News archives
-
Title
Date
